MeSH term
Frequency | Condition_Probility | Humans | 315 | 0.0 |
United States | 2 | 0.0 |
Amino Acid Substitution | 4 | 0.0 |
Animals | 162 | 0.0 |
Body Weight | 3 | 0.0 |
Cell Line | 26 | 0.0 |
Disease Models, Animal | 4 | 0.0 |
Ferrets | 2 | 22.0 |
In Vitro | 18 | 0.0 |
Mice | 23 | 0.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Mutagenesis, Site-Directed | 15 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Virus Replication | 2 | 0.0 |
Aged | 30 | 0.0 |
Aged, 80 and over | 9 | 0.0 |
Cells, Cultured | 20 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Middle Aged | 54 | 0.0 |
Research Support, Non-U.S. Gov't | 190 | 0.0 |
Isoenzymes/metabolism | 5 | 0.0 |
Lens, Crystalline/*enzymology | 2 | 15.0 |
Na(+)-K(+)-Exchanging ATPase/antagonists & inhibitors/*metabolism | 4 | 80.0 |
Research Support, U.S. Gov't, P.H.S. | 138 | 0.0 |
Sodium/metabolism | 18 | 12.0 |
DNA, Complementary | 5 | 0.0 |
Influenza A Virus, Human/genetics/pathogenicity/*physiology | 2 | 100.0 |
Recombination, Genetic | 2 | 0.0 |
Transcription, Genetic | 6 | 0.0 |
*Virus Replication | 2 | 0.0 |
Hela Cells | 19 | 0.0 |
Na(+)-K(+)-Exchanging ATPase/*metabolism | 28 | 70.0 |
Protein Structure, Tertiary | 5 | 0.0 |
Rubidium/metabolism | 11 | 73.0 |
Amino Acid Sequence | 52 | 0.0 |
Molecular Sequence Data | 56 | 0.0 |
Na(+)-K(+)-Exchanging ATPase/chemistry/genetics/*metabolism | 3 | 100.0 |
Rats | 69 | 0.0 |
Microbial Sensitivity Tests | 3 | 1.0 |
Plaque Assay | 2 | 2.0 |
Angiotensin II/*pharmacology | 2 | 1.0 |
Comparative Study | 52 | 0.0 |
Enzyme Inhibitors/pharmacology | 10 | 0.0 |
Hand/blood supply | 3 | 33.0 |
Male | 94 | 0.0 |
Norepinephrine/pharmacology | 4 | 5.0 |
Vasoconstriction/drug effects | 2 | 5.0 |
Veins/drug effects | 2 | 40.0 |
Chromosome Mapping | 5 | 0.0 |
DNA, Complementary/genetics | 4 | 0.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
Genes, Structural | 4 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Morphogenesis | 2 | 0.0 |
Organ Specificity | 5 | 0.0 |
Protein Subunits | 6 | 1.0 |
Influenza/*drug therapy | 2 | 100.0 |
English Abstract | 14 | 0.0 |
Female | 74 | 0.0 |
Pregnancy | 7 | 0.0 |
Kidney/metabolism | 2 | 0.0 |
Molecular Conformation | 2 | 0.0 |
Na(+)-K(+)-Exchanging ATPase/genetics/*metabolism | 10 | 90.0 |
Signal Transduction | 2 | 0.0 |
Adenosine Triphosphate/metabolism | 12 | 2.0 |
Dose-Response Relationship, Drug | 9 | 0.0 |
Kinetics | 36 | 0.0 |
Ligands | 3 | 0.0 |
Mutation | 7 | 0.0 |
Potassium/metabolism/pharmacology | 2 | 33.0 |
Protein Binding | 7 | 0.0 |
Time Factors | 14 | 0.0 |
Transfection | 21 | 0.0 |
Cloning, Molecular | 19 | 0.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Na(+)-K(+)-Exchanging ATPase/*genetics/*metabolism | 2 | 100.0 |
Phylogeny | 3 | 0.0 |
Sequence Homology, Amino Acid | 12 | 0.0 |
Adult | 74 | 0.0 |
Case-Control Studies | 7 | 0.0 |
Base Sequence | 36 | 0.0 |
Blotting, Western | 17 | 0.0 |
Immunohistochemistry | 12 | 0.0 |
Isoenzymes/chemistry/genetics | 2 | 11.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
Polymerase Chain Reaction | 10 | 0.0 |
Sequence Alignment | 9 | 0.0 |
Sequence Homology, Nucleic Acid | 9 | 0.0 |
Chlorides/metabolism | 2 | 2.0 |
Homeostasis | 3 | 0.0 |
Ion Transport | 2 | 2.0 |
Na(+)-K(+)-Exchanging ATPase/metabolism | 13 | 31.0 |
Potassium/*metabolism | 8 | 16.0 |
Prospective Studies | 3 | 0.0 |
Alleles | 4 | 0.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Cohort Studies | 2 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Genotype | 5 | 0.0 |
Hypertension/*genetics | 3 | 2.0 |
Na(+)-K(+)-Exchanging ATPase/*genetics | 21 | 48.0 |
*Symporters | 2 | 2.0 |
Antiviral Agents/*pharmacology | 3 | 1.0 |
Drug Design | 2 | 0.0 |
Neuraminidase/*antagonists & inhibitors | 2 | 66.0 |
Orthomyxoviridae/*drug effects | 3 | 100.0 |
Sodium-Potassium-Chloride Symporters | 4 | 30.0 |
Chickens | 7 | 0.0 |
Na(+)-K(+)-Exchanging ATPase/*biosynthesis/chemistry/*genetics | 2 | 100.0 |
Heart Ventricles/metabolism | 2 | 11.0 |
Immunoblotting | 6 | 0.0 |
Myocardium/*metabolism | 4 | 1.0 |
Isoenzymes/chemistry/genetics/metabolism | 2 | 6.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
Cell Fractionation | 4 | 1.0 |
Biopsy | 4 | 0.0 |
Myocardium/*enzymology | 8 | 10.0 |
Ouabain/pharmacology | 31 | 51.0 |
Radioligand Assay | 2 | 0.0 |
Liver/enzymology | 2 | 0.0 |
Hamsters | 4 | 0.0 |
Mesocricetus | 2 | 1.0 |
Microsomes/enzymology | 3 | 2.0 |
Models, Molecular | 8 | 0.0 |
Na(+)-K(+)-Exchanging ATPase/*chemistry/*genetics/metabolism | 2 | 100.0 |
Phosphorylation | 14 | 0.0 |
Protein Conformation | 13 | 0.0 |
Na(+)-K(+)-Exchanging ATPase/*genetics/metabolism | 6 | 75.0 |
Calcium/*metabolism | 4 | 0.0 |
Dogs | 16 | 1.0 |
Epithelial Cells/drug effects/metabolism | 2 | 2.0 |
Catalysis | 2 | 0.0 |
Kidney Medulla/enzymology | 3 | 42.0 |
Na(+)-K(+)-Exchanging ATPase/chemistry/*metabolism | 5 | 100.0 |
Swine | 6 | 0.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Rabbits | 8 | 0.0 |
Rats, Wistar | 5 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 22 | 0.0 |
Sodium/*metabolism | 9 | 13.0 |
Adolescent | 17 | 0.0 |
Child | 7 | 0.0 |
Child, Preschool | 3 | 0.0 |
Diabetes Mellitus, Type 1/*genetics | 2 | 0.0 |
HLA-DQ Antigens/*genetics | 2 | 0.0 |
Phenotype | 6 | 0.0 |
Cell Membrane/metabolism | 3 | 0.0 |
Microscopy, Confocal | 3 | 0.0 |
Blood Glucose/metabolism | 2 | 0.0 |
Epinephrine/blood | 6 | 4.0 |
Lactic Acid/blood | 2 | 4.0 |
Norepinephrine/blood | 11 | 5.0 |
Oxidation-Reduction | 2 | 0.0 |
Blood Pressure/drug effects | 3 | 0.0 |
Heart Rate/drug effects | 3 | 1.0 |
Models, Biological | 7 | 0.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Gene Expression | 8 | 0.0 |
RNA, Messenger/*biosynthesis | 2 | 0.0 |
Adenosinetriphosphatase/antagonists & inhibitors | 2 | 25.0 |
Binding Sites | 17 | 0.0 |
Cell Division | 2 | 0.0 |
Enzyme Inhibitors/*pharmacology | 5 | 0.0 |
Lethal Dose 50 | 2 | 3.0 |
Ouabain/*pharmacology | 14 | 77.0 |
Blotting, Northern | 6 | 0.0 |
Vasodilator Agents/*pharmacology | 2 | 4.0 |
Cattle | 11 | 0.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
*Digoxin | 3 | 60.0 |
*Saponins | 5 | 62.0 |
Membrane Potentials/physiology | 2 | 2.0 |
Sodium/pharmacology | 2 | 10.0 |
Kidney/*metabolism | 2 | 1.0 |
Electron Spin Resonance Spectroscopy | 2 | 0.0 |
Sialic Acids/*pharmacology | 2 | 50.0 |
Epithelium/enzymology | 3 | 7.0 |
Na(+)-K(+)-Exchanging ATPase/*analysis | 7 | 77.0 |
COS Cells | 3 | 0.0 |
*Mutation | 4 | 0.0 |
Temperature | 2 | 0.0 |
Corticotropin/blood | 2 | 1.0 |
Na(+)-K(+)-Exchanging ATPase/*physiology | 2 | 100.0 |
Blood Pressure/*physiology | 2 | 2.0 |
Cross-Sectional Studies | 2 | 0.0 |
DNA/analysis | 2 | 0.0 |
Exercise/*physiology | 3 | 0.0 |
*Linkage (Genetics) | 3 | 0.0 |
Polymorphism, Restriction Fragment Length | 5 | 0.0 |
Retrospective Studies | 6 | 0.0 |
Urban Population | 2 | 1.0 |
Drug Resistance | 5 | 0.0 |
Na(+)-K(+)-Exchanging ATPase/*chemistry/genetics | 2 | 100.0 |
Potassium/pharmacology | 3 | 5.0 |
Protein Structure, Secondary | 5 | 0.0 |
Cell Polarity | 2 | 1.0 |
Analysis of Variance | 5 | 0.0 |
Dopamine/blood | 4 | 16.0 |
Chi-Square Distribution | 2 | 0.0 |
Isoenzymes | 3 | 1.0 |
Regression Analysis | 2 | 0.0 |
Erythrocyte Membrane/*metabolism | 4 | 5.0 |
Erythrocytes/*metabolism | 16 | 7.0 |
Horses | 2 | 1.0 |
Na(+)-K(+)-Exchanging ATPase/*blood | 11 | 55.0 |
Potassium/*blood | 6 | 40.0 |
Rubidium/blood | 5 | 71.0 |
Sheep | 12 | 2.0 |
Sodium/*blood | 9 | 42.0 |
Genetic Vectors | 2 | 0.0 |
Macromolecular Substances | 21 | 1.0 |
Na(+)-K(+)-Exchanging ATPase/biosynthesis/*genetics | 2 | 100.0 |
Rats, Sprague-Dawley | 6 | 0.0 |
Potassium/metabolism | 16 | 15.0 |
Sequence Deletion | 2 | 0.0 |
Vanadates/pharmacology | 5 | 3.0 |
Enzyme Inhibitors/*analysis | 2 | 16.0 |
Na(+)-K(+)-Exchanging ATPase/*antagonists & inhibitors | 10 | 55.0 |
Reference Values | 6 | 0.0 |
Calcium/metabolism | 5 | 0.0 |
Isoenzymes/*analysis | 4 | 8.0 |
Kidney/enzymology | 8 | 5.0 |
Myocardium/enzymology | 2 | 2.0 |
Heart Failure, Congestive/*metabolism | 2 | 7.0 |
Muscle, Skeletal/metabolism | 2 | 1.0 |
Enzyme Activation | 3 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
Chimeric Proteins/chemistry/metabolism | 2 | 3.0 |
Structure-Activity Relationship | 10 | 0.0 |
Xenopus | 3 | 0.0 |
Hemagglutinin Glycoproteins, Influenza Virus/genetics | 2 | 66.0 |
Substrate Specificity | 5 | 0.0 |
Brain/metabolism | 2 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
*Chromosome Mapping | 3 | 0.0 |
Exons | 3 | 0.0 |
Gene Library | 4 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Na(+)-K(+)-Exchanging ATPase/chemistry/*genetics | 2 | 100.0 |
Chimeric Proteins/genetics/metabolism | 2 | 2.0 |
Peptide Mapping | 2 | 0.0 |
Heart Failure, Congestive/*enzymology | 2 | 40.0 |
Heart Ventricles | 2 | 3.0 |
Na(+)-K(+)-Exchanging ATPase/analysis/*metabolism | 3 | 75.0 |
Cell Membrane/enzymology | 12 | 5.0 |
Cell Survival | 2 | 0.0 |
Na(+)-K(+)-Exchanging ATPase/*chemistry/*metabolism | 2 | 66.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Cell Line, Transformed | 2 | 0.0 |
*Evoked Potentials, Visual | 3 | 10.0 |
Glycosylation | 4 | 0.0 |
Biological Transport | 12 | 0.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
Chick Embryo | 3 | 0.0 |
Computer Simulation | 2 | 0.0 |
Crystallography, X-Ray | 3 | 0.0 |
Microscopy, Electron | 4 | 0.0 |
*Point Mutation | 3 | 0.0 |
*Protein Structure, Secondary | 2 | 1.0 |
Sialic Acids/pharmacology | 2 | 66.0 |
Molecular Weight | 5 | 0.0 |
Species Specificity | 10 | 0.0 |
Tumor Cells, Cultured | 7 | 0.0 |
Adenosine Triphosphate/pharmacology | 3 | 4.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Erythrocytes/metabolism | 6 | 3.0 |
Neuraminidase/genetics/*metabolism | 2 | 100.0 |
Na(+)-K(+)-Exchanging ATPase/antagonists & inhibitors | 7 | 63.0 |
Gene Expression/physiology | 2 | 0.0 |
Gene Expression Regulation | 4 | 0.0 |
Isoenzymes/genetics | 2 | 0.0 |
Na(+)-K(+)-Exchanging ATPase/genetics | 3 | 25.0 |
Isoenzymes/*metabolism | 5 | 1.0 |
Precipitin Tests | 4 | 0.0 |
Sequence Analysis | 3 | 0.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Prognosis | 2 | 0.0 |
Survival Analysis | 2 | 0.0 |
Xenopus laevis | 5 | 1.0 |
*Reaction Time | 2 | 18.0 |
Hydrolysis | 3 | 0.0 |
DNA Primers | 5 | 0.0 |
Guinea Pigs | 3 | 0.0 |
Erythrocytes/*enzymology | 8 | 1.0 |
Protein Kinase C/*metabolism | 2 | 0.0 |
Influenza A Virus, Human/enzymology/*immunology | 2 | 100.0 |
Influenza Vaccines/*immunology | 3 | 15.0 |
Neuraminidase/*immunology | 5 | 83.0 |
Ouabain/metabolism | 16 | 84.0 |
Tissue Distribution | 6 | 0.0 |
Mice, Inbred Strains | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Influenza A Virus, Human/*immunology | 2 | 6.0 |
Osmolar Concentration | 3 | 0.0 |
Mutagenesis, Insertional | 2 | 0.0 |
Na(+)-K(+)-Exchanging ATPase/chemistry/*genetics/metabolism | 2 | 66.0 |
Virulence | 2 | 0.0 |
Age Factors | 5 | 0.0 |
Heart Diseases/complications | 2 | 25.0 |
Incidence | 2 | 0.0 |
Logistic Models | 2 | 0.0 |
Risk Factors | 3 | 0.0 |
Sex Factors | 2 | 0.0 |
Survival Rate | 2 | 0.0 |
Hydrocortisone/blood | 3 | 0.0 |
Hydrogen-Ion Concentration | 5 | 0.0 |
Na(+)-K(+)-Exchanging ATPase/*antagonists & inhibitors/metabolism | 4 | 100.0 |
Sodium/urine | 2 | 3.0 |
Erythrocyte Membrane/enzymology | 2 | 12.0 |
Na(+)-K(+)-Exchanging ATPase/*deficiency | 2 | 100.0 |
Pedigree | 2 | 0.0 |
Potassium/blood | 7 | 8.0 |
Neurotransmitters/*blood | 2 | 25.0 |
Serotonin/blood | 2 | 5.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Cell Size | 2 | 0.0 |
Potassium Channels/*metabolism | 2 | 5.0 |
Hemagglutinins, Viral/*immunology | 2 | 16.0 |
Electrophysiology | 4 | 0.0 |
DNA Probes | 3 | 0.0 |
Myocardium/*enzymology/metabolism | 2 | 50.0 |
Nucleic Acid Hybridization | 8 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Sensitivity and Specificity | 5 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Na(+)-K(+)-Exchanging ATPase/biosynthesis/genetics/*metabolism | 2 | 66.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Mice, Inbred C3H | 2 | 0.0 |
Epitopes/analysis | 2 | 0.0 |
Fluorescent Antibody Technique | 6 | 0.0 |
Kidney/*enzymology | 3 | 4.0 |
Restriction Mapping | 4 | 0.0 |
Copper/chemistry | 2 | 10.0 |
Fluorides/chemistry/*radiation effects | 2 | 66.0 |
Lithium Compounds/chemistry/*radiation effects | 2 | 50.0 |
Luminescent Measurements | 2 | 2.0 |
Magnesium/chemistry | 2 | 10.0 |
Radiochemistry | 2 | 18.0 |
Silicon/chemistry | 2 | 66.0 |
Sodium/chemistry | 2 | 40.0 |
Antibody Specificity | 3 | 0.0 |
Multigene Family/*genetics | 2 | 1.0 |
Erythrocyte Membrane/*enzymology | 4 | 12.0 |
Na(+)-K(+)-Exchanging ATPase/drug effects/*metabolism | 2 | 40.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Torpedo | 6 | 15.0 |
*Bacterial Proteins | 2 | 1.0 |
Deoxyribonuclease HpaII | 2 | 2.0 |
Deoxyribonucleases, Type II Site-Specific | 2 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
*Variation (Genetics) | 3 | 0.0 |
Brain/enzymology | 3 | 1.0 |
Isomerism | 2 | 0.0 |
Biological Transport, Active | 11 | 6.0 |
Intracellular Fluid/metabolism | 2 | 1.0 |
Na(+)-K(+)-Exchanging ATPase/*biosynthesis/genetics | 2 | 100.0 |
RNA/genetics/isolation & purification | 2 | 1.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Membrane Proteins/analysis | 2 | 1.0 |
Erythrocytes/enzymology | 2 | 0.0 |
Electric Stimulation | 3 | 1.0 |
Mathematics | 4 | 2.0 |
Blood Pressure/physiology | 3 | 1.0 |
Cold | 2 | 1.0 |
Hypertension/blood/*metabolism | 2 | 25.0 |
Lipids/*metabolism | 2 | 0.0 |
Na(+)-K(+)-Exchanging ATPase/metabolism/*physiology | 2 | 100.0 |
Sodium/*pharmacokinetics | 2 | 100.0 |
DNA/genetics | 3 | 0.0 |
Plasmids | 2 | 0.0 |
Isoenzymes/*genetics | 2 | 0.0 |
Oligonucleotide Probes | 2 | 0.0 |
Neuraminidase/*metabolism | 2 | 22.0 |
Digitalis Glycosides/*metabolism | 2 | 100.0 |
Myocardial Contraction/drug effects | 2 | 5.0 |
Erythrocyte Membrane/drug effects/*enzymology | 2 | 50.0 |
Na(+)-K(+)-Exchanging ATPase/antagonists & inhibitors/*blood | 2 | 100.0 |
Gastric Mucosa/*enzymology | 2 | 14.0 |
H(+)-K(+)-Exchanging ATPase | 2 | 66.0 |
Kidney Transplantation | 2 | 1.0 |
*Cloning, Molecular | 3 | 0.0 |
DNA/genetics/isolation & purification | 2 | 0.0 |
Peptide Fragments/chemistry | 2 | 1.0 |
Renin/*blood | 2 | 2.0 |
Sodium/blood | 5 | 4.0 |
Na(+)-K(+)-Exchanging ATPase/analysis | 2 | 50.0 |
Biological Transport, Active/drug effects | 6 | 10.0 |
Hemodynamic Processes/drug effects | 3 | 1.0 |
Radioimmunoassay | 4 | 0.0 |
Na(+)-K(+)-Exchanging ATPase/*antagonists & inhibitors/blood | 2 | 100.0 |
*Renal Dialysis | 2 | 0.0 |
Ultrafiltration | 2 | 3.0 |
*Dextrans | 2 | 50.0 |
Ethylmaleimide/pharmacology | 3 | 5.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Myometrium/*blood supply | 2 | 40.0 |
*Genes, Structural | 3 | 0.0 |
Inositol/metabolism | 2 | 8.0 |
*Gene Amplification | 3 | 0.0 |
Membrane Potentials | 2 | 0.0 |
Phentolamine/pharmacology | 2 | 9.0 |
Vasoconstriction/*drug effects | 2 | 5.0 |
Sympathetic Nervous System/*physiology | 2 | 4.0 |
Lymphocytes/*enzymology | 2 | 2.0 |
Rubidium/*blood | 2 | 100.0 |
Cell Membrane/*enzymology | 2 | 7.0 |
Ion Channels/*metabolism | 3 | 7.0 |
Furosemide/pharmacology | 3 | 20.0 |
Biological Transport/drug effects | 3 | 1.0 |
Ion Channels/*drug effects | 2 | 22.0 |
Sodium/*metabolism/pharmacology | 3 | 100.0 |
Epithelium/metabolism | 2 | 0.0 |
Inositol/*metabolism | 2 | 40.0 |
Sciatic Nerve/metabolism | 2 | 14.0 |
Sorbitol/*metabolism | 2 | 100.0 |
Imidazoles/*pharmacology | 2 | 2.0 |
Renal Dialysis | 2 | 0.0 |
Vanadates | 2 | 28.0 |
Vanadium/pharmacology | 2 | 22.0 |
Brain/*enzymology | 2 | 1.0 |
DNA/*analysis | 2 | 0.0 |
Hela Cells/enzymology | 3 | 8.0 |
Rubidium/diagnostic use | 2 | 66.0 |
4-Nitrophenylphosphatase/metabolism | 2 | 100.0 |
X-Rays | 2 | 1.0 |
Trypsin/pharmacology | 2 | 1.0 |
Lithium/metabolism | 2 | 25.0 |
Dinoprost | 2 | 5.0 |
Prostaglandins F/pharmacology | 2 | 14.0 |
Erythrocytes/immunology | 2 | 0.0 |
Brain Chemistry/drug effects | 3 | 18.0 |
Ca(2+)-Transporting ATPase/antagonists & inhibitors | 2 | 12.0 |
Cats | 2 | 0.0 |
Ion Channels/metabolism | 2 | 7.0 |
Sodium/*blood/pharmacology | 2 | 100.0 |
